Individualized Longitudinal ctDNA Monitoring in Melanoma Using Multiplexed USE-PCR
Molecular Diagnosis & Therapy · 2026-09 · 30 (5) · 783-794
DOI: 10.1007/s40291-026-00862-5 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Diagnosis & Therapy, online erschienen am 02.07.2026. Verfasst von Annalara G Fischer und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, University of Louisville, Louisville, KY, USA. Hauptthemen laut MEDLINE: Melanoma, Circulating Tumor DNA, Multiplex Polymerase Chain Reaction, Biomarkers, Tumor. Die Arbeit nennt 23 Literaturangaben. Gefördert von: NIH HHS, NIH.
Abstract (Originalsprache)
BACKGROUND AND OBJECTIVE: Circulating tumor DNA enables longitudinal monitoring in cancer, but current sequencing-based assays are limited by cost, turnaround time, performance in difficult genomic regions, and infrequent sampling. Universal Signal Encoding PCR (USE-PCR) is a highly multiplexed digital PCR chemistry that enables measurement of up to 32 tumor-informed targets per reaction. Here, we evaluated USE-PCR for dense longitudinal circulating tumor DNA monitoring in patients with metastatic melanoma undergoing immunotherapy. METHODS: Tumor and plasma sequencing identified subject-specific variants from nine subjects with melanoma, including variants in GC-rich and historically challenging loci such as the TERT promoter. Subject-specific USE-PCR panels were designed using an automated cloud workflow and applied to plasma cell-free DNA and matched peripheral blood mononuclear cell sample DNA, with up to 21 timepoints per subject, collected over a 2-year window. Variant allele fractions were quantified on a commercial digital PCR platform and interpreted with a peripheral blood mononuclear cell genomic DNA background. CONCLUSIONS: USE-PCR resolved variant-specific circulating tumor DNA trajectories across longitudinal plasma samples. Dense sampling revealed rapid and low-level circulating tumor DNA shifts, including subclonal variants below the 0.2% variant allele fraction that may not be captured through less frequent surveillance intervals. Panels supported the incorporation of new variants without compromising analytical performance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pathology and Laboratory Medicine, University of Louisville, Louisville, KY, USA.
- UofL Health Brown Cancer Center, Louisville, KY, USA.
- Department of Medicine, University of Louisville, Louisville, KY, USA.
- Department of Microbiology and Immunology, University of Louisville, Louisville, KY, USA.
- ChromaCode, Inc., Carlsbad, CA, USA.
- Department of Pathology and Laboratory Medicine, University of Louisville, Louisville, KY, USA. mwlind01@louisville.edu.
Förderung
- NIH HHS
- NIH
Zitieren
APA
Fischer, A. G., Miller, H. A., Hall, M. B., Yadannapudi, K., Jacky, L., Alvarado, J., Aguiar, A., Clark, N., Belitz, P., Myslinski, J., Flook, P., Schwartz, J. J., & Linder, M. W. (2026). Individualized Longitudinal ctDNA Monitoring in Melanoma Using Multiplexed USE-PCR. Molecular Diagnosis & Therapy, 30(5), 783-794. https://doi.org/10.1007/s40291-026-00862-5
Vancouver
Fischer AG, Miller HA, Hall MB, Yadannapudi K, Jacky L, Alvarado J, et al. Individualized Longitudinal ctDNA Monitoring in Melanoma Using Multiplexed USE-PCR. Molecular Diagnosis & Therapy. 2026;30(5):783-794. doi:10.1007/s40291-026-00862-5
BibTeX
@article{Fischer2026,
author = {Fischer, Annalara G and Miller, Hunter A and Hall, Melissa B and Yadannapudi, Kavitha and Jacky, Lucien and Alvarado, John and Aguiar, Aaron and Clark, Nathaniel and Belitz, Paul and Myslinski, Jeremy and Flook, Paul and Schwartz, Jerrod J and Linder, Mark W},
title = {Individualized Longitudinal ctDNA Monitoring in Melanoma Using Multiplexed USE-PCR},
journal = {Molecular Diagnosis & Therapy},
year = {2026},
volume = {30},
number = {5},
pages = {783--794},
doi = {10.1007/s40291-026-00862-5}
}
EUVIMED